New publication in European Urology Oncology: quality of life and progression

Red Door Analytics published research investigating the relationship between quality of life (QoL) and disease progression or death in metastatic hormone-sensitive prostate cancer (mHSPC). The study analysed data from two large phase III randomised trials — ARASENS and ARANOTE — using joint models that simultaneously examine longitudinal QoL trajectories and time-to-event outcomes.

The findings indicate that patients receiving darolutamide maintained higher QoL over time compared to placebo. Additionally, QoL decline often preceded progression or death, with faster deterioration associated with higher risk of these outcomes. These results support routine QoL monitoring as an early marker of disease activity.